Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 4,227 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Completed Phase 2 Interventional Results available

Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)

NCT02432846
View directory record Official record
Conditions
Renal Cell Carcinoma, Metastatic
Interventions
Intuvax (INN: ilixadencel), Sunitinib
Biological · Drug
Lead sponsor
Mendus
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
5
States / cities
Chicago, Illinois • Iowa City, Iowa • Saint Paul, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Phase 2 Interventional

A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients

NCT00001086
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
55
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CYP2B6 Genetics and Drug Interactions in Healthy Volunteers

NCT02401256
View directory record Official record
Conditions
Healthy
Interventions
Efavirenz, Bupropion, Rosuvastatin, Montelukast
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 49 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 20, 2026, 1:45 AM EDT
Terminated Phase 1 Interventional Results available

Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation

NCT04397796
View directory record Official record
Conditions
COVID
Interventions
BM-Allo.MSC, Placebo
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Lynwood, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone

NCT00324896
View directory record Official record
Conditions
Parkinson's Disease, Insomnia
Interventions
eszopiclone, placebo
Drug · Other
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
35 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Suwanee, Georgia • Edison, New Jersey • Piscataway, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Phase 3 Interventional

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

NCT04987203
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Tivozanib, Nivolumab
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 130 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
36
States / cities
Duarte, California • Irvine, California • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Phase 3 Interventional Results available

Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers

NCT01594762
View directory record Official record
Conditions
Diabetic Foot Infection
Interventions
Topical pexiganan cream 0.8%, Topical placebo cream, Standard wound care
Drug · Other
Lead sponsor
Dipexium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Phase 2 Interventional

TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)

NCT00413205
View directory record Official record
Conditions
Emphysema
Interventions
Placebo, RAR Gamma
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
44 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Bot-based Self-help Program (WELL)

NCT06208566
View directory record Official record
Conditions
Well-Being, Psychological
Interventions
Conversational Agent Zenny, Web-based Wellness Resources
Behavioral
Lead sponsor
University of Klagenfurt
Other
Eligibility
18 Years and older
Enrollment
1,595 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Phase 3 Interventional

Topical Antifungal Treatment for Tinea Pedis

NCT01396785
View directory record Official record
Conditions
Tinea Pedis
Interventions
33525, Placebo
Drug
Lead sponsor
Medicis Global Service Corporation
Industry
Eligibility
12 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Los Angeles, California • Paramus, New Jersey • Albuquerque, New Mexico + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 20, 2026, 1:45 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

NCT04565015
View directory record Official record
Conditions
Primary Immune Deficiency
Interventions
GC5107
Biological
Lead sponsor
GC Biopharma Corp
Industry
Eligibility
2 Years to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Aurora, Colorado • Centennial, Colorado • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Phase 3 Interventional Results available

BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus

NCT00603291
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 20, 2026, 1:45 AM EDT
Recruiting Phase 3 Interventional

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

NCT07621718
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
Interventions
Zoldonrasib, Placebo, Oxaliplatin, Leucovorin (Calcium Folinate), 5-Fluorouracil, Irinotecan, Gemcitabine (GEM), Nab-paclitaxel
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

NIRS Guidance Trail in Children's Heart Surgery

NCT02157597
View directory record Official record
Conditions
Heart Defects, Congenital
Interventions
NIRS based management, Control
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Day to 6 Months
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 20, 2026, 1:45 AM EDT
Recruiting Not applicable Interventional

AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions

NCT06959524
View directory record Official record
Conditions
Coronary Arterial Disease (CAD), de Novo Lesions in Native Coronary Arteries
Interventions
Drug Eluting Balloon, Drug eluting stent, Plain old balloon angioplasty
Device · Procedure
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
47
States / cities
Jonesboro, Arkansas • La Jolla, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 1:45 AM EDT
Recruiting Phase 2 Interventional

Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia

NCT02989025
View directory record Official record
Conditions
Pregnancy, Preeclampsia (PE)
Interventions
17 OHPC
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Phase 4 Interventional Results available

Steroids in Bilateral Total Knee Replacement

NCT01399268
View directory record Official record
Conditions
Postoperative Inflammatory Response
Interventions
Hydrocortisone, Saline
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Results available

Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx

NCT00071890
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin 2, HAART, Treatment interruption
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2010 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Phase 4 Interventional Results available

Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation

NCT04792190
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
dapagliflozin, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Portland, Maine • Detroit, Michigan • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Phase 3 Interventional Results available

Tenecteplase in Stroke Patients Between 4.5 and 24 Hours

NCT03785678
View directory record Official record
Conditions
THROMBOLYSIS
Interventions
Tenecteplase, Placebo
Biological · Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
94
States / cities
Birmingham, Alabama • Mesa, Arizona • Anaheim, California + 74 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 20, 2026, 1:45 AM EDT
Active, not recruiting Not applicable Interventional

A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation

NCT07187115
View directory record Official record
Conditions
Atrial Fibrillation (AF), Persistant Atrial Fibrillation
Interventions
FARAPOINT Pulsed Field Ablation System, OptiMap System (non-ablative), FARAPULSE Pulsed Field Ablation (PFA) System and Opal HDx Mapping System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
11
States / cities
Jonesboro, Arkansas • Santa Monica, California • Athens, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis

NCT03427125
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Tenapanor, Placebo, Sevelamer Carbonate
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
The Bronx, New York • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus

NCT01007097
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
TAK-875, Glimepiride, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
64
States / cities
Birmingham, Alabama • Hoover, Alabama • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 20, 2026, 1:45 AM EDT
Completed Phase 1Phase 2 Interventional

NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa

NCT05083260
View directory record Official record
Conditions
Parkinson Disease
Interventions
NE3107, placebo
Drug
Lead sponsor
BioVie Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
16
States / cities
Englewood, Colorado • Boca Raton, Florida • Hallandale, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 20, 2026, 1:45 AM EDT